Department of Renal Medicine, Auckland District Health Board, Auckland, New Zealand; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
ANZDATA Registry, SA Health and Medical Research Institute, Adelaide, Australia; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
Am J Kidney Dis. 2022 Jan;79(1):15-23.e1. doi: 10.1053/j.ajkd.2021.05.021. Epub 2021 Jul 16.
RATIONALE & OBJECTIVE: Patients on home hemodialysis (HHD) may eventually return to in-center hemodialysis (ICHD) for clinical, technical, or psychosocial reasons. We studied the mortality of patients returning to ICHD after HHD, comparing it with the mortality experience among patients receiving HHD and patients receiving ICHD without prior treatment with HHD.
Retrospective cohort study.
SETTING & PARTICIPANTS: All patients represented in the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) who commenced HD during 2005-2015 and were treated for >90 days.
ICHD and/or HHD, and clinical characteristics at study entry.
Mortality and cause of death.
A time-varying multivariate Cox proportional hazards analysis with shared frailty was implemented to explore the association between patient treatment states and mortality. Patients were censored at the time of transplantation or change in treatment modality to peritoneal dialysis.
A total of 19,306 patients initiated HD and were treated for >90 days. The mean age of patients was 60.8 ± 15.4 (SD) years, 62% were male, and 49% had diabetes. After HHD treatment failure, adjusted mortality was increased compared with continued HHD at 0-30 days (HR, 3.93 [95% CI, 2.09-7.40]; P < 0.001), 30-90 days (HR, 3.34 [95% CI, 1.98-5.62]; P < 0.001), and >90 days (HR, 2.29 [95% CI, 1.84-2.85]; P < 0.001).
Covariates recorded at dialysis initiation, residual confounding underlying successful initiation of HHD treatment, and observational data lacking detail on cause of HHD treatment failure.
HHD treatment failure is associated with a significant increase in mortality compared with continued HHD. This risk was present in both the early (first 30 days and 30-90 days) and late (>90 days) periods after HHD treatment failure. Further investigation into the specific causes of treatment failure and death may highlight specific high-risk patients.
接受家庭血液透析(HHD)治疗的患者可能因临床、技术或社会心理原因最终转回中心血液透析(ICHD)治疗。本研究旨在比较 HHD 治疗失败后转回 ICHD 治疗患者与继续接受 HHD 治疗及未接受 HHD 治疗而直接接受 ICHD 治疗患者的死亡率,以评估 HHD 治疗失败后转回 ICHD 治疗患者的预后。
回顾性队列研究。
纳入 2005 年至 2015 年期间在澳大利亚和新西兰透析和移植登记处(ANZDATA)登记并接受 HHD 治疗超过 90 天的所有患者。
ICHD 和/或 HHD 治疗以及研究入组时的临床特征。
死亡率和死亡原因。
采用时间依赖性多变量 Cox 比例风险分析和共享脆弱性模型,以探讨患者治疗状态与死亡率之间的关联。将患者在接受肾移植或治疗模式改变为腹膜透析时进行删失。
共纳入 19306 例开始接受 HD 治疗且治疗超过 90 天的患者。患者的平均年龄为 60.8±15.4(SD)岁,62%为男性,49%患有糖尿病。HHD 治疗失败后,与继续 HHD 治疗相比,0-30 天(HR 3.93,95%CI 2.09-7.40;P<0.001)、30-90 天(HR 3.34,95%CI 1.98-5.62;P<0.001)和>90 天(HR 2.29,95%CI 1.84-2.85;P<0.001)时的死亡率更高。
仅在透析开始时记录协变量,无法完全控制 HHD 治疗成功启动的潜在混杂因素,且观察性数据缺乏 HHD 治疗失败原因的详细信息。
与继续接受 HHD 治疗相比,HHD 治疗失败与死亡率显著升高相关,且这种风险在 HHD 治疗失败后早期(前 30 天和 30-90 天)和晚期(>90 天)均存在。进一步研究 HHD 治疗失败和死亡的具体原因可能会发现特定的高危患者。